SARMs, steroids, and peptides stacked together: what the science says

What did @hormoni_asll actually say?

Honestly? Not much that can be fact-checked. The transcript attached to this video is a stream-of-consciousness rap fragment with no health claims whatsoever. The caption is a different story. In Kurdish, it translates roughly to: "everything that shares in your well-being is available (SARMs, steroids, peptides)." That caption is doing the real work here, and it is advertising a stack of three distinct pharmacological categories to a Kurdish-speaking gym audience across Sulaymaniyah, Erbil, and Duhok.

There are no dosing claims, no mechanism explanations, and no specific compounds named beyond those three categories. What the post is clearly doing is normalizing the concurrent use of SARMs, anabolic steroids, and peptides as a package deal for "well-being." That framing deserves scrutiny.

Does the science back this up?

Peptides like BPC-157 or TB-500 have emerging preclinical data behind them. SARMs and steroids are a different conversation entirely, and bundling all three into one "well-being" package misrepresents what the evidence actually supports.

Peptides occupy a spectrum. BPC-157 has shown accelerated tendon and gut healing in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), and GHK-Cu has demonstrated collagen synthesis activity in vitro (Pickart et al., 2015, Journal of Aging Research). These are real signals. But human clinical trial data remains thin across almost all research peptides.

SARMs are a harder problem. Selective androgen receptor modulators were developed to avoid the systemic side effects of anabolic steroids, but a 2023 FDA safety review flagged serious concerns including liver toxicity, cardiovascular risk, and hormonal suppression in both sexes. The "selective" claim has not held up cleanly in humans.

Anabolic steroids carry the most documented risk profile, including cardiomyopathy, lipid dysregulation, and endocrine disruption (Baggish et al., 2017, Circulation). Framing any combination of these three as broadly accessible "well-being" products is not supported by the evidence base.

What did they get wrong (or right)?

The caption gets something directionally right: these three categories are genuinely popular in gym communities across the Middle East and Central Asia, and peptides in particular are a legitimate area of active research. Acknowledging they exist is not wrong.

What it gets wrong is the bundling. Grouping research peptides with anabolic steroids and SARMs under a single "well-being" umbrella flattens extremely different risk profiles into one marketable phrase. Peptides like ipamorelin or CJC-1295 work on growth hormone secretion pathways. Anabolic steroids work on androgen receptors systemically. SARMs attempt tissue selectivity with inconsistent results. These are not interchangeable tools.

The post also implies availability and accessibility as a selling point. In most jurisdictions, anabolic steroids require a prescription. SARMs are not approved for human use by any major regulatory body. Research peptides occupy a legal gray zone. Presenting all three as casually available is, at minimum, misleading to an audience that may not have access to medical supervision.

• No specific compounds are named, so no specific efficacy claims can be evaluated
• The risk profiles across the three categories vary dramatically
• Casual availability framing ignores regulatory and safety realities

What should you actually know?

If you are considering any compound in these three categories, the most important thing is that stacking them without medical supervision is not a wellness strategy. It is a pharmacological experiment with your endocrine system.

Research peptides like BPC-157, TB-500, and growth hormone secretagogues such as ipamorelin have shown promising signals in animal studies and early human research for recovery and healing applications. But promising signals are not clinical approvals. None of these peptides are FDA-approved for the indications gym communities typically use them for.

SARMs have caused documented liver injury. The FDA issued specific warnings in 2017 and again in updated 2023 guidance. At least one SARM-linked case resulted in a liver transplant. That is not a theoretical risk.

Anabolic steroids, when used outside of supervised medical protocols for conditions like hypogonadism, carry well-documented cardiovascular consequences. A longitudinal study by Baggish et al. (2017, Circulation) found that long-term anabolic steroid users had significantly impaired left ventricular function compared to non-users.

Anyone in the Kurdish gym communities these hashtags target deserves accurate information. A post that makes all three categories sound equally accessible and benign is not giving them that.